| Ulcerative Colitis

Amjevita vs Remicade

Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.

Deep comparison between: Amjevita vs Remicade with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRemicade has a higher rate of injection site reactions vs Amjevita based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Remicade but not Amjevita, including UnitedHealthcare

Category

Amjevita

Remicade

At A Glance

RouteSC injection

FrequencyEvery other week

ClassTNF-alpha antagonist

RouteIV infusion

FrequencyEvery 8 weeks

ClassTNF-alpha inhibitor

Indications

Rheumatoid Arthritis
Juvenile arthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Crohn Disease
Ulcerative Colitis
Psoriasis vulgaris
Hidradenitis Suppurativa
Uveitis

Crohn Disease
Ulcerative Colitis
Rheumatoid Arthritis
Arthritis, Psoriatic
Psoriasis vulgaris

Dosing

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis Adults: 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.

Juvenile arthritis, Uveitis (pediatric, >=2 years) Weight-based SC every other week: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), 40 mg (>=30 kg).

Crohn Disease (adults) 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29.

Crohn Disease (pediatric, >=6 years) Weight-based: 80 mg Day 1 / 40 mg Day 15 / 20 mg every other week (17 to <40 kg); 160 mg Day 1 / 80 mg Day 15 / 40 mg every other week (>=40 kg).

Ulcerative Colitis Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.

Psoriasis vulgaris, Uveitis (adults) 80 mg SC initial dose, then 40 mg every other week starting one week after the initial dose.

Hidradenitis Suppurativa (adults) 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.

Hidradenitis Suppurativa (adolescents >=12 years, >=30 kg) Weight-based: 80 mg Day 1 / 40 mg every other week from Day 8 (30 to <60 kg); 160 mg Day 1 / 80 mg Day 15 / 40 mg weekly or 80 mg every other week from Day 29 (>=60 kg).

Crohn Disease, Ulcerative Colitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks (adults and pediatric patients >= 6 years).

Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; dose may be increased up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete responders.

Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks.

Contraindications

—

Doses >5 mg/kg in patients with moderate or severe heart failure
Previous severe hypersensitivity reaction to infliximab, any inactive ingredient of REMICADE, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)

Drug Interactions

1222View drug interactions

1225View drug interactions

Adverse Reactions

Most common (>=5%) Injection site reactions, upper respiratory infection, sinusitis, headache, rash, nausea, urinary tract infection, flu syndrome, abdominal pain, back pain, hypertension.

Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, hypersensitivity reactions, hepatitis B virus reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.

Postmarketing Diverticulitis, large bowel perforations, pancreatitis, pyrexia, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis.

Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain.

Serious Pneumonia, cellulitis, abscess, sepsis, bacterial infection, hepatotoxicity, acute liver failure, malignancies (including lymphoma), pancytopenia, thrombocytopenia, leukopenia.

Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction.

Pharmacology

Adalimumab-atto is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, inhibiting TNF-mediated inflammatory and immune responses; it also lyses surface TNF-expressing cells in vitro in the presence of complement and modulates downstream biological responses including adhesion molecule expression (ELAM-1, VCAM-1, ICAM-1).

TNF-alpha antagonist; infliximab is a chimeric IgG1 monoclonal antibody that neutralizes the biological activity of TNF-alpha by binding with high affinity to both soluble and transmembrane forms of TNF-alpha and inhibiting its binding to receptors, thereby reducing inflammation in RA, CD, UC, AS, PsA, and Ps.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Amjevita